Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 for prevention of topotecan-induced myelosuppression in TP53-mutant extensive-stage small cell lung cancer
NL-OMON49367Phase 2Active, not recruiting
- Sponsor
- Rein Therapeutics
- Start
- Sep 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of sulanemadlin in myelosuppression, sponsored by Rein Therapeutics. Started Sep 2019; status: active, not recruiting.
02
Drugs
sulanemadlin
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NL-OMON49367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49367.